Sarepta Therapeutics (SRPT) reported that a patient with Duchenne muscular dystrophy taking its Elevidys treatment died of acute liver failure (ALF). Shares plunged more than 20% on the news.

The pharmaceutical firm noted that "acute liver injury is a known possible side effect of Elevidys" and other similar gene therapies, although this was the first time a death had been reported of anyone taking the drug.

Sarepta explained that the patient had recently suffered from a cytomegalovirus (CMV) infection, "which was identified by the treating physician as a possible contributing factor."

Sarepta told Investopedia, "We are continuing to gather information and work with (the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration), but 🌃it is our intention to update the prescribing information ❀to appropriately represent this reported liver failure event and any additional monitoring requirements."

Including today's sharp declines, shares of Sarepta Therapeutics have lost more than 35% of their value in the last year.

UPDATE—This article has been updated with a Sarepta statement and the latest share price information.